ASXInvite to Investor Webinar on Symphony RCT
other announcement
ARX
Aroa Biosurgery
Pharmaceuticals, Biotechnology & Life Sciences
AROA Biosurgery Limited specializes in regenerative healing products for soft-tissue repair. It emphasizes the use of extracellular matrix (ECM) biomaterials in its offerings, giving it a niche position in the medical devices market. The company aims to improve healing outcomes and reduce healthcare costs, standing out through its innovative solutions and successful commercialization strategies.
Short position
short percentage0.00%
reported shorts18
shares on issue345.903M
Aroa Biosurgery (ASX:ARX) has 0.00% of its shares on issue reported as short positions as of 1 Oct 2026, or about 18 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.47% in August 2023. ARX is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Aroa Biosurgery (ARX) News
Latest articles and price-sensitive announcements with AI sentiment classification.
Investor Presentation - MASTRR Interim Analysis
other announcement
KalkineASX Healthcare Stock Aroa Biosurgery (ASX:ARX) Has the Market Watching
Highlights Aroa Biosurgery has attracted renewed attention after clinical results for its Symphony wound-care product. The companys diabetic foot ulcer data showed a stronger wound-closure outcome when Symphony was used alongside standard care. Myriad remains an established commercial driver while Symphony adds another avenue across the outpatient wound-care market. The Australian share market remains focused on company-specific developments as changing economic conditions and global unc...
StockheadAroa Biosurgery boosts Symphony clinical case with faster diabetic wound healing
Results from a US trial have strengthened ARX’s evidence base for Symphony in diabetic foot ulcers, achieving improved healing alongside ... Read More The post Aroa Biosurgery boosts Symphony clinical case with faster diabetic wound healing appeared first on Stockhead.
Symphony Significantly Improves DFU Healing
other announcement
Invite to Investor Webinar on MASTRR Interim Analysis
other announcement
Google NewsAroa Biosurgery (ASX:ARX) in Focus: Could This ASX Biotech Stock Be One to Watch in September 2026? - Kalkine
Aroa Biosurgery (ASX:ARX) in Focus: Could This ASX Biotech Stock Be One to Watch in September 2026? Kalkine
Dr Boreham’s Crucible: Aroa Biosurgery’s wound care products are ‘the sheep’s guts’
Aroa Biosurgery has turned sheep guts into a growing wound care business, with US sales driving it into profit and ... Read More The post Dr Boreham’s Crucible: Aroa Biosurgery’s wound care products are ‘the sheep’s guts’ appeared first on Stockhead.
Major study finds low infection rates for Aroa’s Myriad bioscaffold
Aroa has announced peer-reviewed publication of interim results from its ongoing MASTRR Registry ... Read More The post Major study finds low infection rates for Aroa’s Myriad bioscaffold appeared first on Stockhead.
Myriad MASTRR Study Reports Low Infection Rates
other announcement
Change of Director's Interest Notice - BW
director_dealing announcement
Aroa Biosurgery Limited (ASX:ARX) Share Price Rises 0.85% as Stock Trades Within Daily Range - Kalkine
Aroa Biosurgery Limited (ASX:ARX) Share Price Rises 0.85% as Stock Trades Within Daily Range Kalkine
Aroa Biosurgery Ltd (ASX: ARX) Share Price Update: Stock Declines Slightly as Health Care Index Ends Lower - Kalkine
Aroa Biosurgery Ltd (ASX: ARX) Share Price Update: Stock Declines Slightly as Health Care Index Ends Lower Kalkine
Aroa Biosurgery sharpens wound healing focus with senior commercial hires
The soft-tissue regeneration company has appointed Michael Lynskey as chief commercial officer and Mike Falcon as general manager – United ... Read More The post Aroa Biosurgery sharpens wound healing focus with senior commercial hires appeared first on Stockhead.
AROA Biosurgery Limited Grants 2.9 Million Restricted Stock Units to Employees Under Incentive Plan
AROA Biosurgery Limited has announced the allocation of 2,900,172 restricted stock units (RSUs) as part of its employee incentive program. This move underscores the company’s dedication to aligning employee interests with shareholder value in the highly competitive biotechnology industry. Key Points AROA Biosurgery Limited (ASX: ARX) Issued 2,900,172 restricted stock units on July 22, 2026. Financial details related to the issuance remain undisclosed. Investors are monitoring potential impa...
Long Shortz with Aroa Biosurgery: Symphony remains well positioned under CMS proposal
Aroa's Brian Ward and Zack Bridges unpack the proposed CMS reimbursement update and what it means for Symphony. ... Read More The post Long Shortz with Aroa Biosurgery: Symphony remains well positioned under CMS proposal appeared first on Stockhead.
_07_03_2026_03_50_21_133108.jpg&w=3840&q=65)
Aroa Biosurgery Reports Expiry and Lapse of Over 4 Million Securities Affecting Equity Structure
Aroa Biosurgery Limited has disclosed the cessation of more than 4 million securities, including options and performance rights, due to expiry and unmet conditions. This significant update impacts the company’s equity composition and reflects strict adherence to the terms governing its securities. Key Points Aroa Biosurgery Limited (ARX) Termination of 4,413,708 securities comprising options and performance rights Critical dates: June 28, June 30, and July 7, 2026 Investors advised to monit...
Aroa Biosurgery (ASX:ARX) in focus as reimbursement clarity approaches
Highlights A regenerative wound-care developer moved into focus ahead of clearer United States reimbursement rules. The second half of the financial year shapes as a decisive stretch for the name. Larger ASX healthcare leaders provided a steadier backdrop to open the week. Aroa Biosurgery (ASX:ARX), a developer of regenerative products that help the body repair soft tissue and heal complex wounds, drew fresh attention as the market turned to the prospect of clearer reimbursement rules across it...
Why Aroa Biosurgery (ASX:ARX) Shares Are Under Pressure Today - Kalkine
Why Aroa Biosurgery (ASX:ARX) Shares Are Under Pressure Today Kalkine
Aroa Biosurgery Director John Diddams Sells 200,000 Shares for $125,789 - Kalkine
Aroa Biosurgery Director John Diddams Sells 200,000 Shares for $125,789 Kalkine
Change of Director's Interest Notice - JD
director_dealing announcement
Notice of AGM Date and Director Nomination Closing Date
other announcement
Aroa Biosurgery (ASX:ARX) Beats FY26 Guidance as Myriad Drives 54% Growth Surge - Kalkine
Aroa Biosurgery (ASX:ARX) Beats FY26 Guidance as Myriad Drives 54% Growth Surge Kalkine
Long Shortz with Aroa Biosurgery: ARX delivers breakout FY26 results
Aroa has delivered breakout FY26 results, with record revenue, strong EBITDA growth and rising momentum from its Myriad product portfolio. ... Read More The post Long Shortz with Aroa Biosurgery: ARX delivers breakout FY26 results appeared first on Stockhead.
What’s Fueling Fresh Buzz Around Aroa BioSurgery?
Highlights Aroa BioSurgery continues expanding its regenerative wound care footprint across international healthcare markets. Product innovation and hospital adoption trends remain central to the company’s commercial momentum. Regulatory pathways, healthcare spending trends and manufacturing execution continue shaping sector sentiment. Aroa BioSurgery continues expanding within regenerative healthcare as innovation, hospital adoption trends and healthcare demand shape attention ac...
Aroa beats FY26 guidance as Myriad drives 54% growth surge
Aroa delivers strong FY26, beating revenue and earnings guidance as rapid growth from its Myriad wound care portfolio continues to ... Read More The post Aroa beats FY26 guidance as Myriad drives 54% growth surge appeared first on Stockhead.
Small CapsAroa Biosurgery (ASX:ARX) prints NZ$12.6m EBITDA then guides it lower for FY27 - Stocks Down Under
Aroa Biosurgery (ASX:ARX) prints NZ$12.6m EBITDA then guides it lower for FY27 Stocks Down Under
Aroa beats guidance as Myriad growth drives strong FY26 performance
Aroa Biosurgery has topped NZ$100 million in annual revenue for the first time, beating FY26 guidance on sales and earnings ... Read More The post Aroa beats guidance as Myriad growth drives strong FY26 performance appeared first on Stockhead.
Aroa Biosurgery (ASX:ARX) Guidance smashed by A$4m, Myriad growth at 52% does the heavy lifting - Stocks Down Under
Aroa Biosurgery (ASX:ARX) Guidance smashed by A$4m, Myriad growth at 52% does the heavy lifting Stocks Down Under
Canaccord in tune with Aroa Biosurgery on Symphony’s US opportunity
Canaccord sees meaningful upside in Aroa Biosurgery, as US reimbursement reforms create a more favourable backdrop for its upcoming Symphony ... Read More The post Canaccord in tune with Aroa Biosurgery on Symphony’s US opportunity appeared first on Stockhead.
Stock Market Spotlight: Breakthrough in Wound Care as (ASX:ARX) Advances Trial
Highlights Symphony study reaches key clinical milestone Improved healing outcomes seen in trial group Strengthens pathway toward wider medical adoption Aroa Biosurgery has completed a major clinical study for its Symphony product, highlighting improved healing in complex diabetic wounds and reinforcing its position within advanced wound care innovation. Aroa Biosurgery Strengthens Clinical Footprint with Symphony Study Completion Aroa Biosurgery (ASX:ARX) has taken a meaningful step fo...